XNAS · Healthcare · Biotechnology
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q3 2026 | -0.27 | -0.24 | +11.11% | $0 | ✅ Beat | -0.86% | -4.13% | — |
| 2026-02-12 | Q2 2026 | -0.23 | -0.26 | -13.04% | $0 | ❌ Miss | +0.34% | -4.41% | +3.62% |
| 2025-11-14 |
| Q1 2026 |
| -0.33 |
| -0.22 |
| +33.33% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-09-22 | Q4 2025 | -0.30 | -0.42 | -40.00% | $0 | ❌ Miss | — | — | — |
| 2025-02-14 | Q2 2025 | -0.58 | -0.33 | +43.10% | $0 | ✅ Beat | +0.09% | +0.44% | +36.36% |
| 2024-11-14 | Q1 2025 | -0.43 | -0.48 | -11.63% | $0 | ❌ Miss | +2.69% | -1.92% | +20.96% |
| 2024-09-26 | Q4 2024 | -0.43 | -0.60 | -39.53% | $0 | ❌ Miss | +5.01% | +11.60% | +21.96% |
| 2024-05-13 | Q3 2024 | -0.78 | -1.64 | -110.26% | $0 | ❌ Miss | +3.82% | +28.94% | -8.00% |
Showing last 8 quarters.